NAD+ precursor supplements are generally well tolerated in oral form at the doses used in clinical trials, but they are not risk-free. The safety picture depends heavily on what form you take (oral capsules vs. IV infusions), how much you take, and whether you have an existing health condition like cancer. Here’s what the current evidence actually shows.
What “NAD+ Supplements” Actually Means
Your body naturally produces NAD+ (nicotinamide adenine dinucleotide), a molecule involved in energy production, DNA repair, and cellular aging. You can’t absorb NAD+ itself very well through your gut, so most supplements contain precursors that your body converts into NAD+. The two most common are nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN). These are sold as over-the-counter supplements, not prescription drugs, which means they aren’t held to the same manufacturing or testing standards as pharmaceuticals.
IV NAD+ infusions, offered at wellness clinics, are a different category entirely and carry distinct risks covered below.
What Human Trials Show About Oral Safety
Most clinical trials have tested NR at doses between 250 mg and 2,000 mg per day. A randomized controlled trial published in The Lancet’s eClinicalMedicine gave participants 2,000 mg of NR daily (split into two doses of four 250 mg capsules) for 10 weeks without reporting serious safety concerns. That’s on the high end of what’s been studied.
The side effects reported in trials at these doses tend to be mild: flushing, nausea, headaches, diarrhea, and stomach discomfort. These typically resolve on their own or with a lower dose. NMN has been studied in fewer and smaller human trials, but early results at doses up to 1,250 mg per day have shown a similar side-effect profile.
One important caveat: “well tolerated in a 10-week trial” is not the same as “safe for years of daily use.” Long-term safety data simply doesn’t exist yet for either NR or NMN at any dose. Most trials last weeks to a few months, with relatively small groups of participants.
The Cancer Concern Worth Knowing About
This is probably the most significant open question around NAD+ supplementation. NAD+ helps cells repair themselves and stay energized, which sounds great for healthy cells. But cancer cells also need energy and self-renewal, and research from Washington University School of Medicine found that the NAD+ production pathway is overactive in glioblastoma, an aggressive form of brain cancer. In that study, glioblastoma patients whose tumors had high expression of a key NAD+ pathway gene (NAMPT) died sooner. When researchers blocked that gene in mice, tumors shrank. When they left it active, tumors grew rapidly.
The senior researcher on that study, Albert H. Kim, put it plainly: the team didn’t directly demonstrate that taking NAD+ precursors makes tumors grow faster, but one implication of the work is that people considering these supplements should know “we don’t yet understand all the risks.” The concern isn’t that NAD+ causes cancer. It’s that if you already have cancer cells in your body, even ones you don’t know about, boosting NAD+ could theoretically help those cells thrive. This remains a theoretical risk, not a proven one, but it’s grounded in real biology rather than speculation.
IV NAD+ Infusions Carry Real Risks
The FDA has specifically warned about NAD+ given intravenously at compounding pharmacies and wellness clinics. The core problem is that many compounders use food-grade NAD+ to make injectable products. Food-grade ingredients aren’t processed to the sterility standards required for something going directly into your bloodstream, which creates a high risk of contamination with bacteria and endotoxins.
The FDA has received adverse event reports following IV NAD+ use, including severe chills, shaking, vomiting, and fatigue serious enough to require medical treatment. These reactions are consistent with endotoxin contamination. If you’re considering IV NAD+, the risks are meaningfully higher than with oral supplements, and the evidence that IV delivery provides additional benefits over oral precursors is thin.
Drug Interactions
NAD+ precursors can interact with other medications. Nicotinamide, a related B vitamin in the same metabolic family, has 111 known drug interactions documented on pharmaceutical databases, with 7 classified as major (meaning the combination should be avoided) and 100 classified as moderate. NR and NMN share enough metabolic overlap with nicotinamide that similar interactions are plausible, though they haven’t been cataloged as thoroughly.
If you take medications for blood pressure, blood thinning, diabetes, or liver conditions, the potential for interaction is higher. The supplement’s effects on cellular metabolism can alter how your body processes certain drugs.
No FDA Approval or Standardization
Neither NR nor NMN is FDA-approved as a drug. They’re sold as dietary supplements, which means manufacturers don’t have to prove safety or effectiveness before selling them. What’s on the label may not match what’s in the bottle. Third-party testing (look for NSF International or USP verification on packaging) offers some assurance of purity and accurate dosing, but it’s voluntary.
NMN’s regulatory status has been particularly messy. The FDA briefly considered classifying it as a new dietary ingredient that couldn’t be sold as a supplement, which created confusion in the market. Some NMN products were pulled and then returned. If you’re buying NMN specifically, verify that the product is currently legally sold and independently tested.
Who Should Be Most Cautious
Based on the available evidence, certain groups face higher potential risk from NAD+ supplementation:
- People with a current or recent cancer diagnosis. The theoretical risk that boosted NAD+ could fuel tumor growth makes this a situation where the potential downside is serious, even if unproven.
- People taking multiple medications. The number of known drug interactions with related compounds is high enough to warrant checking with a pharmacist before adding NAD+ precursors.
- Anyone considering IV infusions. The contamination risks flagged by the FDA are not theoretical. Adverse events have already been reported.
For otherwise healthy adults taking oral NR or NMN at doses within the range used in clinical trials (typically 250 to 1,000 mg per day for NR), short-term use appears to be low risk based on available data. The honest answer, though, is that the long-term safety profile remains unknown, and the supplement industry’s lack of standardization adds a layer of uncertainty that pharmaceutical drugs don’t have.